RxDoctor Payments Data

Jonathan Harrison, MD

Cardiovascular Disease · Murray, UTNPI 1053739821

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (56.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Boston Scientific at 24.7% of the total. Reporting peaked in 2022 at $2,524 and has fallen 78.2% since, to $551 in 2025.

$4,974in general payments, 2019–2025

Across 40 payments — averaging $124.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • W. L. Gore & Associates, Inc.$1K
  • Penumbra, Inc.$1K
  • Shockwave Medical, Inc$587
  • Abbott$289
  • Abiomed$145
  • plus $489 from 6 others

What the payments were for

  • Travel & lodging$2,81056%
  • Food & beverage$1,91438%
  • Education$2515%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,974 in reported general payments places this provider in the 70th percentile of 131 cardiovascular disease providers in Utah.

See all cardiovascular disease providers in Utah

Medicare billing

Part B allowed, 2024
$50,414
Medicare patients
162
Services billed
349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban42$52,301
FarxigaDapagliflozin Propanediol29$39,747
JardianceEmpagliflozin25$29,350
Metoprolol Succinate95$1,466
Atorvastatin Calcium109$1,145
Spironolactone88$860
Isosorbide Mononitrate ErIsosorbide Mononitrate44$663
ClopidogrelClopidogrel Bisulfate59$617
Carvedilol54$491
Losartan Potassium44$445
Rosuvastatin Calcium35$412
Ezetimibe22$315
Furosemide39$260
Pantoprazole Sodium20$186
Lisinopril29$181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$96$52,30142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 131 cardiovascular disease providers in Utah.

Other cardiovascular disease in Murray

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →